Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2008 1
2009 2
2010 1
2011 1
2014 1
2015 2
2016 1
2017 3
2018 2
2019 3
2020 3
2021 7
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes.
Cunnea P, Curry EW, Christie EL, Nixon K, Kwok CH, Pandey A, Wulandari R, Thol K, Ploski J, Morera-Albert C, McQuaid S, Lozano-Kuehne J, Clark JJ, Krell J, Stronach EA, McNeish IA, Bowtell DDL, Fotopoulou C. Cunnea P, et al. Cell Rep Med. 2023 Jun 20;4(6):101055. doi: 10.1016/j.xcrm.2023.101055. Epub 2023 May 22. Cell Rep Med. 2023. PMID: 37220750 Free PMC article.
Clinicopathological characteristics and survival outcomes of patients with large cell neuroendocrine carcinoma of the uterine cervix: A systematic review and meta-analysis.
Prodromidou A, Phelps DL, Pergialiotis V, Cunnea P, Thomakos N, Rodolakis A, Fotopoulou C, Haidopoulos D. Prodromidou A, et al. Among authors: cunnea p. Eur J Obstet Gynecol Reprod Biol. 2022 Mar;270:212-220. doi: 10.1016/j.ejogrb.2022.01.014. Epub 2022 Jan 17. Eur J Obstet Gynecol Reprod Biol. 2022. PMID: 35093830 Review.
Validation analysis of the novel imaging-based prognostic radiomic signature in patients undergoing primary surgery for advanced high-grade serous ovarian cancer (HGSOC).
Fotopoulou C, Rockall A, Lu H, Lee P, Avesani G, Russo L, Petta F, Ataseven B, Waltering KU, Koch JA, Crum WR, Cunnea P, Heitz F, Harter P, Aboagye EO, du Bois A, Prader S. Fotopoulou C, et al. Among authors: cunnea p. Br J Cancer. 2022 Apr;126(7):1047-1054. doi: 10.1038/s41416-021-01662-w. Epub 2021 Dec 18. Br J Cancer. 2022. PMID: 34923575 Free PMC article.
Tumor Growth Rate Estimates Are Independently Predictive of Therapy Response and Survival in Recurrent High-Grade Serous Ovarian Cancer Patients.
Bartl T, Karacs J, Kreuzinger C, Pfaffinger S, Kendler J, Ciocsirescu C, Wolf A, Reinthaller A, Meyer E, Brandstetter M, Postl M, Langthaler E, Braicu E, Vergote I, Cunnea P, Gourley C, Schmitt WD, Cacsire Castillo-Tong D, Christoph G. Bartl T, et al. Among authors: cunnea p. Cancers (Basel). 2021 Mar 3;13(5):1076. doi: 10.3390/cancers13051076. Cancers (Basel). 2021. PMID: 33802395 Free PMC article.
The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers.
Hu Z, Cunnea P, Zhong Z, Lu H, Osagie OI, Campo L, Artibani M, Nixon K, Ploski J, Santana Gonzalez L, Alsaadi A, Wietek N, Damato S, Dhar S, Blagden SP, Yau C, Hester J, Albukhari A, Aboagye EO, Fotopoulou C, Ahmed A. Hu Z, et al. Among authors: cunnea p. Clin Cancer Res. 2021 Mar 1;27(5):1570-1579. doi: 10.1158/1078-0432.CCR-20-2782. Epub 2021 Jan 14. Clin Cancer Res. 2021. PMID: 33446563
29 results